{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:25:13Z","timestamp":1789568713139,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["transDATA study: BOOG 2006-01, D5392-NL-003-Substudy"],"award-info":[{"award-number":["transDATA study: BOOG 2006-01, D5392-NL-003-Substudy"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters are used for risk prediction. DNA methylation markers have been proven to be of additional prognostic value in several cancer types. Numerous prognostic DNA methylation markers for breast cancer have been published in the literature. However, to date, none of these markers are used in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a systematic review of PubMed and EMBASE to assess the number and level of evidence of published DNA methylation markers for hormone receptor-positive breast cancer. To obtain an overview of the reporting quality of the included studies, all were scored according to the REMARK criteria that were established as reporting guidelines for prognostic biomarker studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 74 studies were identified reporting on 87 different DNA methylation markers. Assessment of the REMARK criteria showed variation in reporting quality of the studies. Eighteen single markers and one marker panel were studied in multiple independent populations. Hypermethylation of the markers <jats:italic>RASSF1<\/jats:italic>, <jats:italic>BRCA<\/jats:italic>, <jats:italic>PITX2<\/jats:italic>, <jats:italic>CDH1<\/jats:italic>, <jats:italic>RARB<\/jats:italic>, <jats:italic>PCDH10<\/jats:italic> and <jats:italic>PGR<\/jats:italic>, and the marker panel <jats:italic>GSTP1<\/jats:italic>, <jats:italic>RASSF1<\/jats:italic> and <jats:italic>RARB<\/jats:italic> showed a statistically significant correlation with poor disease outcome that was confirmed in at least one other, independent study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This systematic review provides an overview on published prognostic DNA methylation markers for hormone receptor-positive breast cancer and identifies eight markers that have been independently validated. Analysis of the reporting quality of included studies suggests that future research on this topic would benefit from standardised reporting guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-020-1250-9","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T11:02:49Z","timestamp":1580468569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review"],"prefix":"10.1186","volume":"22","author":[{"given":"Tim C.","family":"de Ruijter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van der Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"van Engeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C. G.","family":"Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"1250_CR1","volume-title":"Global cancer facts & figures","author":"American Cancer society","year":"2015","unstructured":"American Cancer society. Global cancer facts & figures. 3rd ed. Atlanta: American Cancer Society; 2015.","edition":"3"},{"issue":"10001","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"M Dowsett","year":"2015","unstructured":"Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet."},{"issue":"19","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"9814","key":"1250_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432\u201344.","journal-title":"Lancet."},{"issue":"5","key":"1250_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejso.2011.02.001","volume":"37","author":"GC Wishart","year":"2011","unstructured":"Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol. 2011;37(5):411\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533\u201346.","journal-title":"Ann Oncol"},{"issue":"12","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.2005.06.178","volume":"23","author":"IA Olivotto","year":"2005","unstructured":"Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23(12):2716\u201325.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1250_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"N Denduluri","year":"2016","unstructured":"Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2016;34(20):2416\u201327.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMe1512092","volume":"373","author":"CA Hudis","year":"2015","unstructured":"Hudis CA. Biology before anatomy in early breast cancer--precisely the point. N Engl J Med. 2015;373(21):2079\u201380.","journal-title":"N Engl J Med"},{"issue":"8","key":"1250_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"1250_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/febs.13125","volume":"282","author":"J Jeschke","year":"2015","unstructured":"Jeschke J, Collignon E, Fuks F. DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment. FEBS J. 2015;282(9):1801\u201314.","journal-title":"FEBS J"},{"issue":"3","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.molonc.2014.10.012","volume":"9","author":"OA Stefansson","year":"2015","unstructured":"Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2015;9(3):555\u201368.","journal-title":"Mol Oncol"},{"issue":"Suppl 1","key":"1250_CR14","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ncponc0354","volume":"2","author":"SB Baylin","year":"2005","unstructured":"Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(Suppl 1):S4\u201311.","journal-title":"Nat Clin Pract Oncol"},{"issue":"4","key":"1250_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0168-9525(99)01971-X","volume":"16","author":"SB Baylin","year":"2000","unstructured":"Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168\u201374.","journal-title":"Trends Genet"},{"issue":"4","key":"1250_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1045","volume":"3","author":"PW Laird","year":"2003","unstructured":"Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.","journal-title":"PLoS Med"},{"issue":"10","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nmeth.2632","volume":"10","author":"KB Michels","year":"2013","unstructured":"Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Greally JM, Gut I, et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods. 2013;10(10):949\u201355.","journal-title":"Nat Methods"},{"issue":"7","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"1","key":"1250_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-012-2117-2","volume":"135","author":"JZ Cerne","year":"2012","unstructured":"Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, et al. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012;135(1):135\u201343.","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","volume":"88","author":"DF Hayes","year":"1996","unstructured":"Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456\u201366.","journal-title":"J Natl Cancer Inst"},{"key":"1250_CR22","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. 2011. http:\/\/www.cebm.net\/indexaspx?o=5653."},{"issue":"15","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127\u201332.","journal-title":"J Clin Oncol"},{"key":"1250_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1741-7015-10-51","volume":"10","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51.","journal-title":"BMC Med"},{"issue":"4","key":"1250_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387\u201391.","journal-title":"Br J Cancer"},{"issue":"6","key":"1250_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4149\/neo_2012_079","volume":"59","author":"SG Angelova","year":"2012","unstructured":"Angelova SG, Krasteva ME, Gospodinova ZI, Georgieva EI. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients. Neoplasma. 2012;59(6):622\u201330.","journal-title":"Neoplasma."},{"issue":"2","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-006-9241-9","volume":"100","author":"T Arai","year":"2006","unstructured":"Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat. 2006;100(2):169\u201376.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1250_CR28","first-page":"2975","volume":"31","author":"A Buhmeida","year":"2011","unstructured":"Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, et al. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res. 2011;31(9):2975\u201381.","journal-title":"Anticancer Res"},{"issue":"9","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1111\/j.1349-7006.2009.01225.x","volume":"100","author":"Y Chen","year":"2009","unstructured":"Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci. 2009;100(9):1663\u20137.","journal-title":"Cancer Sci"},{"issue":"10","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1541-7786.MCR-13-0096","volume":"11","author":"M Chimonidou","year":"2013","unstructured":"Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol Cancer Res. 2013;11(10):1248\u201357.","journal-title":"Mol Cancer Res"},{"key":"1250_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1471-2407-10-247","volume":"10","author":"D Dietrich","year":"2010","unstructured":"Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer. 2010;10:247.","journal-title":"BMC Cancer"},{"issue":"1","key":"1250_CR32","first-page":"9","volume":"7","author":"SA Ebeid","year":"2016","unstructured":"Ebeid SA, El Moneim NAA, Hewala TIM, Hemida MA, Shehata G, El-Taher N. Assessment of hypermethylation of RASSF1A and protocadherin-10 tumor suppressor genes in breast cancer females: a six-year disease-free survival case-control study. Middle East J Cancer. 2016;7(1):9\u201320.","journal-title":"Middle East J Cancer"},{"issue":"75","key":"1250_CR33","doi-asserted-by":"publisher","first-page":"75ra25","DOI":"10.1126\/scitranslmed.3001875","volume":"3","author":"F Fang","year":"2011","unstructured":"Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3(75):75ra25.","journal-title":"Sci Transl Med"},{"issue":"12","key":"1250_CR34","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1096\/fj.12-209502","volume":"26","author":"M Faryna","year":"2012","unstructured":"Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 2012;26(12):4937\u201350.","journal-title":"FASEB J"},{"issue":"11","key":"1250_CR35","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-07-4557","volume":"14","author":"H Fiegl","year":"2008","unstructured":"Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, et al. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008;14(11):3494\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1250_CR36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-04-2438","volume":"65","author":"H Fiegl","year":"2005","unstructured":"Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65(4):1141\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"1250_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2009.06.007","volume":"41","author":"DY Fu","year":"2010","unstructured":"Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Shen ZZ, et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol. 2010;41(1):48\u201358.","journal-title":"Hum Pathol"},{"issue":"1","key":"1250_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3892\/ol.2014.2068","volume":"8","author":"N Fujita","year":"2014","unstructured":"Fujita N, Kagara N, Yamamoto N, Shimazu K, Shimomura A, Shimoda M, et al. Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis. Oncol Lett. 2014;8(1):397\u2013403.","journal-title":"Oncol Lett"},{"issue":"5","key":"1250_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000342083","volume":"83","author":"N Fujita","year":"2012","unstructured":"Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, et al. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology. 2012;83(5):273\u201382.","journal-title":"Oncology."},{"issue":"1","key":"1250_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-010-1335-8","volume":"130","author":"G Gobel","year":"2011","unstructured":"Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, Muller-Holzner E, et al. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat. 2011;130(1):109\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"1250_CR41","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1200\/JCO.2007.14.1697","volume":"26","author":"N Harbeck","year":"2008","unstructured":"Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grutzmann R, et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol. 2008;26(31):5036\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1250_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/1078-0432.CCR-08-0166","volume":"15","author":"O Hartmann","year":"2009","unstructured":"Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res. 2009;15(1):315\u201323.","journal-title":"Clin Cancer Res"},{"key":"1250_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1476-4598-9-51","volume":"9","author":"VK Hill","year":"2010","unstructured":"Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer. 2010;9:51.","journal-title":"Mol Cancer"},{"issue":"8","key":"1250_CR44","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/0008-5472.CAN-10-4026","volume":"71","author":"VK Hill","year":"2011","unstructured":"Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71(8):2988\u201399.","journal-title":"Cancer Res"},{"key":"1250_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1479-5876-11-245","volume":"11","author":"YT Huang","year":"2013","unstructured":"Huang YT, Li FF, Ke C, Li Z, Li ZT, Zou XF, et al. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med. 2013;11:245.","journal-title":"J Transl Med"},{"issue":"2","key":"1250_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2008.01.001","volume":"13","author":"E Iorns","year":"2008","unstructured":"Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 2008;13(2):91\u2013104.","journal-title":"Cancer Cell"},{"issue":"9","key":"1250_CR47","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1002\/jcp.26562","volume":"233","author":"R Jahangiri","year":"2018","unstructured":"Jahangiri R, Mosaffa F, Emami Razavi A, Teimoori-Toolabi L, Jamialahmadi K. Altered DNA methyltransferases promoter methylation and mRNA expression are associated with tamoxifen response in breast tumors. J Cell Physiol. 2018;233(9):7305\u201319.","journal-title":"J Cell Physiol"},{"issue":"1\u20132","key":"1250_CR48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000155145","volume":"75","author":"F Jing","year":"2008","unstructured":"Jing F, Jun L, Yong Z, Wang Y, Fei X, Zhang J, et al. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology. 2008;75(1\u20132):60\u20136.","journal-title":"Oncology."},{"issue":"1","key":"1250_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4048\/jbc.2013.16.1.16","volume":"16","author":"SP Jung","year":"2013","unstructured":"Jung SP, Kim S, Nam SJ, Kim I, Bae JW. The role of the CDH1 promoter hypermethylation in the axillary lymph node metastasis and prognosis. J Breast Cancer. 2013;16(1):16\u201322.","journal-title":"J Breast Cancer"},{"issue":"2","key":"1250_CR50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00432-009-0649-6","volume":"136","author":"S Karray-Chouayekh","year":"2010","unstructured":"Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, et al. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol. 2010;136(2):203\u201310.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1250_CR51","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/ijc.24686","volume":"125","author":"M Kioulafa","year":"2009","unstructured":"Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, et al. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer. 2009;125(12):2887\u201392.","journal-title":"Int J Cancer"},{"issue":"10\u201311","key":"1250_CR52","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.clinbiochem.2009.04.003","volume":"42","author":"M Kioulafa","year":"2009","unstructured":"Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem. 2009;42(10\u201311):970\u20135.","journal-title":"Clin Biochem"},{"issue":"6","key":"1250_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/annonc\/mdn733","volume":"20","author":"M Kioulafa","year":"2009","unstructured":"Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol. 2009;20(6):1020\u20135.","journal-title":"Ann Oncol"},{"key":"1250_CR54","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/1471-2407-13-456","volume":"13","author":"J Klajic","year":"2013","unstructured":"Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 2013;13:456.","journal-title":"BMC Cancer"},{"issue":"1","key":"1250_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4149\/neo_2012_011","volume":"59","author":"ME Krasteva","year":"2012","unstructured":"Krasteva ME, Bozhanov SS, Antov GG, Gospodinova ZI, Angelov SG. Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status. Neoplasma. 2012;59(1):85\u201391.","journal-title":"Neoplasma."},{"issue":"2","key":"1250_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.canlet.2005.06.011","volume":"237","author":"S Li","year":"2006","unstructured":"Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett. 2006;237(2):272\u201380.","journal-title":"Cancer Lett"},{"key":"1250_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2156-15-67","volume":"15","author":"SY Li","year":"2014","unstructured":"Li SY, Li R, Chen YL, Xiong LK, Wang HL, Rong L, et al. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients. BMC Genet. 2014;15:67.","journal-title":"BMC Genet"},{"issue":"4","key":"1250_CR58","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.3892\/ol.2016.4274","volume":"11","author":"J Liu","year":"2016","unstructured":"Liu J, Sun X, Qin S, Wang H, Du N, Li Y, et al. CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol Lett. 2016;11(4):2635\u201343.","journal-title":"Oncol Lett"},{"issue":"4","key":"1250_CR59","first-page":"4462","volume":"16","author":"W Liu","year":"2018","unstructured":"Liu W, Wu J, Shi G, Yue X, Liu D, Zhang Q. Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer. Oncol Lett. 2018;16(4):4462\u201370.","journal-title":"Oncol Lett"},{"issue":"3","key":"1250_CR60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-010-1168-5","volume":"126","author":"L Lu","year":"2011","unstructured":"Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat. 2011;126(3):687\u201394.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1250_CR61","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.ejca.2007.04.025","volume":"43","author":"S Maier","year":"2007","unstructured":"Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer (Oxford). 2007;43(11):1679\u201386.","journal-title":"Eur J Cancer (Oxford)"},{"key":"1250_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2407-14-59","volume":"14","author":"J Martinez-Galan","year":"2014","unstructured":"Martinez-Galan J, Torres-Torres B, Nunez MI, Lopez-Penalver J, Del Moral R, Ruiz De Almodovar JM, et al. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer. 2014;14:59.","journal-title":"BMC Cancer"},{"issue":"1","key":"1250_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-010-1160-0","volume":"129","author":"AT Martins","year":"2011","unstructured":"Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, Leal C, et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat. 2011;129(1):1\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1250_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-007-9757-7","volume":"111","author":"O Mc Cormack","year":"2008","unstructured":"Mc Cormack O, Chung WY, Fitzpatrick P, Cooke F, Flynn B, Harrison M, et al. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer. Breast Cancer Res Treat. 2008;111(1):45\u201353.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1250_CR65","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/1078-0432.CCR-03-0514","volume":"10","author":"J Mehrotra","year":"2004","unstructured":"Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, et al. Estrogen receptor\/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004;10(6):2052\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4\u20135","key":"1250_CR66","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clinbiochem.2009.11.016","volume":"43","author":"S Mirza","year":"2010","unstructured":"Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem. 2010;43(4\u20135):380\u20136.","journal-title":"Clin Biochem"},{"issue":"9","key":"1250_CR67","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1245\/s10434-012-2323-5","volume":"19","author":"S Mirza","year":"2012","unstructured":"Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012;19(9):3107\u201315.","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"1250_CR68","first-page":"7641","volume":"63","author":"HM Muller","year":"2003","unstructured":"Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003;63(22):7641\u20135.","journal-title":"Cancer Res"},{"issue":"3","key":"1250_CR69","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-007-9800-8","volume":"111","author":"I Nimmrich","year":"2008","unstructured":"Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2008;111(3):429\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"1250_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1471-2407-8-154","volume":"8","author":"E Noetzel","year":"2008","unstructured":"Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer. 2008;8:154.","journal-title":"BMC Cancer"},{"issue":"2","key":"1250_CR71","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/bjc.2012.231","volume":"107","author":"C Palmieri","year":"2012","unstructured":"Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, et al. Methylation of the calcium channel regulatory subunit alpha2delta-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br J Cancer. 2012;107(2):375\u201381.","journal-title":"Br J Cancer"},{"issue":"6","key":"1250_CR72","doi-asserted-by":"publisher","first-page":"e100429","DOI":"10.1371\/journal.pone.0100429","volume":"9","author":"SY Park","year":"2014","unstructured":"Park SY, Seo AN, Jung HY, Gwak JM, Jung N, Cho NY, et al. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer. PLoS One. 2014;9(6):e100429.","journal-title":"PLoS One"},{"issue":"12","key":"1250_CR73","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-10-2950","volume":"17","author":"TN Pathiraja","year":"2011","unstructured":"Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, et al. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011;17(12):4177\u201386.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1250_CR74","doi-asserted-by":"publisher","first-page":"23944","DOI":"10.18632\/oncotarget.4062","volume":"6","author":"N Perez-Janices","year":"2015","unstructured":"Perez-Janices N, Blanco-Luquin I, Torrea N, Liechtenstein T, Escors D, Cordoba A, et al. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. Oncotarget. 2015;6(27):23944\u201358.","journal-title":"Oncotarget."},{"key":"1250_CR75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2407-10-23","volume":"10","author":"EA Ramos","year":"2010","unstructured":"Ramos EA, Camargo AA, Braun K, Slowik R, Cavalli IJ, Ribeiro EM, et al. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer. 2010;10:23.","journal-title":"BMC Cancer"},{"issue":"6","key":"1250_CR76","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1007\/s13277-013-0983-9","volume":"34","author":"J Ren","year":"2013","unstructured":"Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, et al. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013;34(6):3945\u201358.","journal-title":"Tumour Biol"},{"issue":"7","key":"1250_CR77","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/carcin\/bgn115","volume":"29","author":"BA Rodriguez","year":"2008","unstructured":"Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, Shapiro CL, et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis. 2008;29(7):1459\u201365.","journal-title":"Carcinogenesis."},{"issue":"3\u20134","key":"1250_CR78","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lfs.2010.05.001","volume":"87","author":"G Sharma","year":"2010","unstructured":"Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010;87(3\u20134):83\u201391.","journal-title":"Life Sci"},{"issue":"6","key":"1250_CR79","first-page":"487","volume":"31","author":"G Sharma","year":"2009","unstructured":"Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, et al. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol. 2009;31(6):487\u2013500.","journal-title":"Cell Oncol"},{"issue":"3","key":"1250_CR80","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-015-3632-8","volume":"154","author":"Y Shen","year":"2015","unstructured":"Shen Y, Wang Z, Loo LW, Ni Y, Jia W, Fei P, et al. LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer. Breast Cancer Res Treat. 2015;154(3):473\u201382.","journal-title":"Breast Cancer Res Treat"},{"key":"1250_CR81","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1038\/oncsis.2016.16","volume":"5","author":"HM Stephen","year":"2016","unstructured":"Stephen HM, Khoury RJ, Majmudar PR, Blaylock T, Hawkins K, Salama MS, et al. Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis. 2016;5:e207.","journal-title":"Oncogenesis."},{"issue":"2","key":"1250_CR82","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-012-2353-5","volume":"137","author":"J Ulirsch","year":"2013","unstructured":"Ulirsch J, Fan C, Knafl G, Wu MJ, Coleman B, Perou CM, et al. Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat. 2013;137(2):383\u201396.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1250_CR83","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10549-012-2038-0","volume":"134","author":"AQ van Hoesel","year":"2012","unstructured":"van Hoesel AQ, van de Velde CJ, Kuppen PJ, Liefers GJ, Putter H, Sato Y, et al. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat. 2012;134(3):1103\u201314.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1250_CR84","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10549-011-1485-3","volume":"131","author":"AQ van Hoesel","year":"2012","unstructured":"van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruijf EM, van Nes JG, et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat. 2012;131(3):859\u201369.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1250_CR85","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.onc.1210669","volume":"27","author":"J Veeck","year":"2008","unstructured":"Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, et al. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene. 2008;27(6):865\u201376.","journal-title":"Oncogene."},{"issue":"5","key":"1250_CR86","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/carcin\/bgn076","volume":"29","author":"J Veeck","year":"2008","unstructured":"Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, et al. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis. 2008;29(5):991\u20138.","journal-title":"Carcinogenesis."},{"key":"1250_CR87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1476-4598-7-83","volume":"7","author":"J Veeck","year":"2008","unstructured":"Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 2008;7:83.","journal-title":"Mol Cancer"},{"issue":"5","key":"1250_CR88","doi-asserted-by":"publisher","first-page":"e37928","DOI":"10.1371\/journal.pone.0037928","volume":"7","author":"S Wang","year":"2012","unstructured":"Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One. 2012;7(5):e37928.","journal-title":"PLoS One"},{"issue":"38","key":"1250_CR89","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1038\/onc.2011.584","volume":"31","author":"EJ Wee","year":"2012","unstructured":"Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, et al. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene. 2012;31(38):4182\u201395.","journal-title":"Oncogene."},{"issue":"2","key":"1250_CR90","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/07357907.2016.1271886","volume":"35","author":"C Weissenborn","year":"2017","unstructured":"Weissenborn C, Ignatov T, Nass N, Kalinski T, Dan Costa S, Zenclussen AC, et al. GPER promoter methylation controls GPER expression in breast cancer patients. Cancer Investig. 2017;35(2):100\u20137.","journal-title":"Cancer Investig"},{"issue":"11","key":"1250_CR91","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1158\/0008-5472.CAN-03-3852","volume":"64","author":"M Widschwendter","year":"2004","unstructured":"Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004;64(11):3807\u201313.","journal-title":"Cancer Res"},{"key":"1250_CR92","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1471-2407-12-243","volume":"12","author":"J Xu","year":"2012","unstructured":"Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, et al. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012;12:243.","journal-title":"BMC Cancer"},{"issue":"2","key":"1250_CR93","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-008-0075-5","volume":"115","author":"X Xu","year":"2009","unstructured":"Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2009;115(2):397\u2013404.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1250_CR94","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/annonc\/mdt011","volume":"24","author":"Y Xu","year":"2013","unstructured":"Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol. 2013;24(6):1498\u2013505.","journal-title":"Ann Oncol"},{"issue":"8","key":"1250_CR95","first-page":"9500","volume":"8","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhang B, Fang J, Cao X. Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. Int J Clin Exp Pathol. 2015;8(8):9500\u20135.","journal-title":"Int J Clin Exp Pathol"},{"issue":"21","key":"1250_CR96","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446\u201352.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1250_CR97","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4161\/epi.20299","volume":"7","author":"R Claus","year":"2012","unstructured":"Claus R, Wilop S, Hielscher T, Sonnet M, Dahl E, Galm O, et al. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics. 2012;7(7):772\u201380.","journal-title":"Epigenetics"},{"issue":"17","key":"1250_CR98","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1002\/cncr.27392","volume":"118","author":"V Quillien","year":"2012","unstructured":"Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012;118(17):4201\u201311.","journal-title":"Cancer."},{"key":"1250_CR99","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13148-016-0211-8","volume":"8","author":"MX Draht","year":"2016","unstructured":"Draht MX, Smits KM, Jooste V, Tournier B, Vervoort M, Ramaekers C, et al. Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome. Clin Epigenetics. 2016;8:44.","journal-title":"Clin Epigenetics"},{"issue":"7","key":"1250_CR100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"1250_CR101","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-10-3394","volume":"17","author":"IJ van Vlodrop","year":"2011","unstructured":"van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 2011;17(13):4225\u201331.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1250_CR102","doi-asserted-by":"publisher","first-page":"e40466","DOI":"10.1371\/journal.pone.0040466","volume":"7","author":"A Stone","year":"2012","unstructured":"Stone A, Valdes-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, et al. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One. 2012;7(7):e40466.","journal-title":"PLoS One"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-1250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-020-1250-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-1250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:30:03Z","timestamp":1611966603000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-1250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-1250-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. dr. Tjan-Heijnen reports grants from AstraZeneca, during the conduct of the study; grants and non-financial support from Roche; grants and non-financial support from Pfizer; grants and non-financial support from Novartis; grants and non-financial support from E Lilly; and grants from Eisai, outside the submitted work. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}